Reducing lipids for CV protection in CKD patients-current evidence.

[1]  C. Wanner,et al.  Lipid abnormalities and cardiovascular risk in renal disease. , 2008, Journal of the American Society of Nephrology : JASN.

[2]  J. Kastelein,et al.  Intensive lipid lowering with atorvastatin in patients with coronary heart disease and chronic kidney disease: the TNT (Treating to New Targets) study. , 2008, Journal of the American College of Cardiology.

[3]  J. Coombes,et al.  The Lipid lowering and Onset of Renal Disease (LORD) Trial: A randomized double blind placebo controlled trial assessing the effect of atorvastatin on the progression of kidney disease , 2008, BMC nephrology.

[4]  G. Kaysen.  Hyperlipidemia in Chronic Kidney Disease , 2007, The International journal of artificial organs.

[5]  M. Landray,et al.  CARDIOVASCULAR AND SURVIVAL PARADOXES IN DIALYSIS PATIENTS: Misleading Associations between Cholesterol and Vascular Outcomes in Dialysis Patients: The Need for Randomized Trials , 2007, Seminars in dialysis.

[6]  P. Ridker,et al.  Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women. , 2007, JAMA.

[7]  B. Nordestgaard,et al.  Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. , 2007, JAMA.

[8]  J. Kastelein,et al.  Dyslipidaemia as predictor of progressive renal failure and the impact of treatment with atorvastatin. , 2007, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[9]  F. Kronenberg,et al.  In vivo turnover study demonstrates diminished clearance of lipoprotein(a) in hemodialysis patients. , 2007, Kidney international.

[10]  L. Cupples,et al.  Determinants of progression from microalbuminuria to proteinuria in patients who have type 1 diabetes and are treated with angiotensin-converting enzyme inhibitors. , 2007, Clinical journal of the American Society of Nephrology : CJASN.

[11]  F. Kronenberg,et al.  Lipoprotein metabolism and lipid management in chronic kidney disease. , 2007, Journal of the American Society of Nephrology : JASN.

[12]  P. Libby,et al.  Apolipoprotein CIII–Induced THP-1 Cell Adhesion to Endothelial Cells Involves Pertussis Toxin–Sensitive G Protein– and Protein Kinase C&agr;–Mediated Nuclear Factor-&kgr;B Activation , 2007, Arteriosclerosis, thrombosis, and vascular biology.

[13]  P. O'Malley,et al.  Meta-Analysis: The Effect of Statins on Albuminuria , 2006, Annals of Internal Medicine.

[14]  M. Tonelli,et al.  Statins for improving renal outcomes: a meta-analysis. , 2006, Journal of the American Society of Nephrology : JASN.

[15]  F. Kronenberg,et al.  Delayed In Vivo Catabolism of Intermediate-Density Lipoprotein and Low-Density Lipoprotein in Hemodialysis Patients as Potential Cause of Premature Atherosclerosis , 2005, Arteriosclerosis, thrombosis, and vascular biology.

[16]  R. Collins,et al.  Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins , 2005, The Lancet.

[17]  W. März,et al.  Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. , 2005, The New England journal of medicine.

[18]  F. Zannad,et al.  Effect of rosuvastatin on outcomes in chronic haemodialysis patients – design and rationale of the AURORA study , 2005, Current controlled trials in cardiovascular medicine.

[19]  Florian Kronenberg,et al.  Renal insulin resistance syndrome, adiponectin and cardiovascular events in patients with kidney disease: the mild and moderate kidney disease study. , 2005, Journal of the American Society of Nephrology : JASN.

[20]  A. Jenkins,et al.  Lipoproteins and diabetic microvascular complications. , 2004, Current pharmaceutical design.

[21]  Elvira Agrón,et al.  Risk factors for renal replacement therapy in the Early Treatment Diabetic Retinopathy Study (ETDRS), Early Treatment Diabetic Retinopathy Study Report No. 26. , 2004, Kidney international.

[22]  G. Assmann,et al.  Raising high-density lipoprotein cholesterol with reduction of cardiovascular risk: the role of nicotinic acid – a position paper developed by the European Consensus Panel on HDL-C* , 2004, Current medical research and opinion.

[23]  S. Hadjadj,et al.  Serum triglycerides are a predictive factor for the development and the progression of renal and retinal complications in patients with type 1 diabetes. , 2004, Diabetes & metabolism.

[24]  N. Powe,et al.  Association between cholesterol level and mortality in dialysis patients: role of inflammation and malnutrition. , 2004, JAMA.

[25]  Sarah Parish,et al.  MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial , 2003, The Lancet.

[26]  F. Sacks,et al.  Effect of pravastatin on loss of renal function in people with moderate chronic renal insufficiency and cardiovascular disease. , 2003, Journal of the American Society of Nephrology : JASN.

[27]  C. Baigent,et al.  Study of Heart and Renal Protection (SHARP). , 2003, Kidney international. Supplement.

[28]  E. Ritz,et al.  The apolipoprotein e knockout mouse: a model documenting accelerated atherogenesis in uremia. , 2003, Journal of the American Society of Nephrology : JASN.

[29]  F. Sacks,et al.  Pravastatin for Secondary Prevention of Cardiovascular Events in Persons with Mild Chronic Renal Insufficiency , 2003, Annals of Internal Medicine.

[30]  A. Sharrett,et al.  Coronary Heart Disease Prediction From Lipoprotein Cholesterol Levels, Triglycerides, Lipoprotein(a), Apolipoproteins A-I and B, and HDL Density Subfractions: The Atherosclerosis Risk in Communities (ARIC) Study , 2001, Circulation.

[31]  B. Staels,et al.  Peroxisome proliterator-activated receptor-alpha activators regulate genes governing lipoprotein metabolism, vascular inflammation and atherosclerosis , 1999 .

[32]  A. Hamsten,et al.  Very Low-Density Lipoprotein Activates Nuclear Factor-κB in Endothelial Cells , 1999 .

[33]  T. Shoji,et al.  Intermediate-density lipoprotein as an independent risk factor for aortic atherosclerosis in hemodialysis patients. , 1998, Journal of the American Society of Nephrology : JASN.

[34]  O. Samuelsson,et al.  Lipoprotein metabolism and renal failure. , 1993, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[35]  Y. Ringel,et al.  Severe defect in clearing postprandial chylomicron remnants in dialysis patients. , 1992, Kidney international.

[36]  E G Lowrie,et al.  Death risk in hemodialysis patients: the predictive value of commonly measured variables and an evaluation of death rate differences between facilities. , 1990, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[37]  M C Hjortland,et al.  High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. , 1977, The American journal of medicine.

[38]  B. Scribner,et al.  Accelerated atherosclerosis in prolonged maintenance hemodialysis. , 1974, The New England journal of medicine.

[39]  K. Zitouni,et al.  Circulating cholesterol as a modulator of risk for renal injury in patients with type 2 diabetes. , 2008, Diabetes research and clinical practice.

[40]  B. Astor,et al.  Lipoprotein abnormalities associated with mild impairment of kidney function in the multi-ethnic study of atherosclerosis. , 2008, Clinical journal of the American Society of Nephrology : CJASN.

[41]  F. Kronenberg,et al.  Apolipoprotein A-IV predicts progression of chronic kidney disease: the mild to moderate kidney disease study. , 2006, Journal of the American Society of Nephrology : JASN.

[42]  M. Carnethon,et al.  Higher levels of HDL cholesterol are associated with a decreased likelihood of albuminuria in patients with long-standing type 1 diabetes. , 2006, Diabetes care.

[43]  T. Marwick,et al.  The effect of long-term aggressive lipid lowering on ischemic and atherosclerotic burden in patients with chronic kidney disease. , 2004, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[44]  Atul Kumar,et al.  The Role of Lipids in the Development of Diabetic Microvascular Complications , 2003, American journal of cardiovascular drugs : drugs, devices, and other interventions.

[45]  B. Kestenbaum,et al.  HMG-CoA reductase inhibitors are associated with reduced mortality in ESRD patients. , 2002, Kidney international.

[46]  F. Kronenberg,et al.  Lipoprotein(a) serum concentrations and apolipoprotein(a) phenotypes in mild and moderate renal failure. , 2000, Journal of the American Society of Nephrology : JASN.

[47]  A. Hamsten,et al.  Very low-density lipoprotein activates nuclear factor-kappaB in endothelial cells. , 1999, Circulation research.

[48]  B. Staels,et al.  Peroxisome proliferator-activated receptor-alpha activators regulate genes governing lipoprotein metabolism, vascular inflammation and atherosclerosis. , 1999, Current opinion in lipidology.

[49]  P. Degoulet,et al.  Mortality risk factors in patients treated by chronic hemodialysis. Report of the Diaphane collaborative study. , 1982, Nephron.